Cargando…

Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway

BACKGROUND: Cisplatin-based chemotherapy is mainstay treatment in urinary bladder cancer (UBC). However, tumor recurrence frequently occurs with the acquisition of cisplatin resistance. We explored the potential effect of a polyherbal preparation, Zyflamend, on UBC cells resistant to cisplatin treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Yanshi, Yang, Lin, Li, Junzun, Yan, Yilin, Jiang, Qinghui, Shen, Lan, Yang, Shuai, Shen, Bing, Huang, Ruimin, Yan, Jun, Guo, Hongqian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072829/ https://www.ncbi.nlm.nih.gov/pubmed/30104883 http://dx.doi.org/10.2147/OTT.S162255

Ejemplares similares

Zyflamend induces apoptosis in pancreatic cancer cells via modulation of the JNK pathway
por: Puckett, Dexter L., et al.
Publicado: (2020)

Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series
por: Bilen, Mehmet Asim, et al.
Publicado: (2015)

TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer
por: Zhuang, Junlong, et al.
Publicado: (2017)

TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT
por: Zhuang, Junlong, et al.
Publicado: (2015)

Zyflamend, a unique herbal blend, induces cell death and inhibits adipogenesis through the coordinated regulation of PKA and JNK
por: Puckett, Dexter, et al.
Publicado: (2020)

PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7
por: Huang, Zhengnan, et al.
Publicado: (2021)

Pao Pereira extract suppresses benign prostatic hyperplasia by inhibiting inflammation-associated NFκB signaling
por: Dong, Yu, et al.
Publicado: (2020)

Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer
por: Dalangood, Sumiya, et al.
Publicado: (2020)

BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer
por: Kuang, Chun-mei, et al.
Publicado: (2017)

Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis
por: Zhang, Qing, et al.
Publicado: (2015)

TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB
por: Xing, Ji, et al.
Publicado: (2022)

Inhibition of the NF-κB Signaling Pathway Alleviates Pyroptosis in Bladder Epithelial Cells and Neurogenic Bladder Fibrosis
por: Chen, Jing, et al.
Publicado: (2023)

Modulation of NF-κB/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to Cisplatin
por: Yang, Zhenhua, et al.
Publicado: (2015)

Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells
por: Huang, E-Chu, et al.
Publicado: (2014)

Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway
por: Ma, Xu, et al.
Publicado: (2017)

TRPA1 promotes cisplatin-induced nephrotoxicity through inflammation mediated by the MAPK/NF-κB signaling pathway
por: Yuan, Jinyan, et al.
Publicado: (2021)

IL‐25 promotes cisplatin resistance of lung cancer cells by activating NF‐κB signaling pathway to increase of major vault protein
por: Shen, Weiming, et al.
Publicado: (2019)

CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10–ERK signaling
por: Huang, Zhengnan, et al.
Publicado: (2021)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Osthole enhances antitumor activity and irradiation sensitivity of cervical cancer cells by suppressing ATM/NF-κB signaling
por: Che, Yilin, et al.
Publicado: (2018)

Transcriptional upregulation of MAPK15 by NF-κB signaling boosts the efficacy of combination therapy with cisplatin and TNF-α
por: Wu, Dan-Dan, et al.
Publicado: (2022)

Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-κB and improving mitochondrial function
por: Yu, Xiaowen, et al.
Publicado: (2018)

α-Synuclein Negatively Regulates Nurr1 Expression Through NF-κB-Related Mechanism
por: Jia, Congcong, et al.
Publicado: (2020)

Combination of BFHY with Cisplatin Relieved Chemotherapy Toxicity and Altered Gut Microbiota in Mice
por: Feng, Yuan, et al.
Publicado: (2023)

IL-17 induces macrophages to M2-like phenotype via NF-κB
por: Shen, Jing, et al.
Publicado: (2018)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

NF-κB signaling mediates acquired resistance after PARP inhibition
por: Nakagawa, Yuko, et al.
Publicado: (2015)

The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway
por: He, Shanyang, et al.
Publicado: (2017)

Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter
por: Jiang, Wei, et al.
Publicado: (2020)

Inhibition of hepatocyte nuclear factor 1β contributes to cisplatin nephrotoxicity via regulation of nf‐κb pathway
por: Zhang, Yan, et al.
Publicado: (2021)

miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness
por: Zhang, Qing, et al.
Publicado: (2017)

NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo
por: Cui, Xiaolu, et al.
Publicado: (2017)

Combination of quercetin and cisplatin enhances apoptosis in OSCC cells by downregulating xIAP through the NF-κB pathway
por: Li, Xin, et al.
Publicado: (2019)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Tim-3 protects against cisplatin nephrotoxicity by inhibiting NF-κB-mediated inflammation
por: Li, Peiyao, et al.
Publicado: (2023)

Establishment of an optimized orthotopic bladder cancer model in mice
por: Cai, Jinming, et al.
Publicado: (2022)

Wentilactone A Reverses the NF-κB/ECM1 Signaling-Induced Cisplatin Resistance through Inhibition of IKK/IκB in Ovarian Cancer Cells
por: Lv, Cuiting, et al.
Publicado: (2022)

Investigation of Bladder Cancer Cell Response to Cryoablation and Adjunctive Cisplatin Based Cryo/Chemotherapy
por: Santucci, Kimberly L, et al.
Publicado: (2020)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

The STAT1/HMGB1/NF-κB pathway in chronic inflammation and kidney injury after cisplatin exposure
por: Fu, Ying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v2eeusodhmovvqv9de7b33ei1h